Quantcast

BioNeutral’s Ogiene(TM) Multipurpose Cleaner Outperforms Currently Used Cleaners at Doubletree Hotel, Jersey City, NJ

October 19, 2010

NEWARK, N.J., Oct. 19 /PRNewswire/ — BioNeutral Group, Inc. (OTC Bulletin Bourd: BONU), a specialty chemical technology-based life science company announced today that it has completed successful testing of its Ogiene(TM) Multipurpose Cleaner at the Doubletree Hotel, Jersey City, a Division of Hartz Mountain Industries, Inc.

BioNeutral’s Ogiene(TM) Multipurpose Cleaner provided excellent performance on a variety of stains which previously could not be removed even by professional cleaners.

Sam Calello, General Manager of the Doubletree Hotel, Jersey City, New Jersey commented, “We tested the BioNeutral Multipurpose Cleaner on several different surfaces that had stains which could not be removed even by professional cleaners. I can honestly say that your product removed stains and gum in our guest room carpeting, elevators, chairs and hallway carpeting. We tried many different products and none of them were able to completely remove the gum and stains. Not only is your product a winner, but it is environmentally safe. We intend to showcase this product, at our next Corporate Meeting, to our Associate hotels – The SoHo Grand Hotel, New York, NY. Tribeca Grand Hotel, New York, NY and the Sheraton Lincoln Harbor Hotel, Weehawken, NJ. We look forward to our first order.”

Dr. Andy Kielbania, Chief Scientist of BioNeutral Group, Inc., added, “These results are a testimonial and a confirmation of the exceptional cleaning power of Ogiene(TM) Multipurpose Cleaner. High-traffic areas like hotels, office buildings and transportation centers are ideal for our Ogiene(TM) Multipurpose Cleaner, once decision-makers see the product in action, we are confident they will want to integrate it into their regular cleaning regimens.”

About the Hartz Group

Headquartered in Secaucus, N.J., Hartz Mountain Industries, Inc. is one of the largest private owners of commercial real estate in the U.S. It has grown from a small start in 1966 to a large regional real estate enterprise, owning and operating a portfolio of 200 buildings in the New York/New Jersey area, and representing more than 38 million square feet of retail, hotel, office and industrial properties. In addition, with more than 200 undeveloped acres of prime land in Northern New Jersey, Hartz is ensuring its future strength and growth for years to come. At Hartz Mountain Industries, the expertise housed under one roof is extraordinary. Hartz is staffed to build even the most complex developments quickly and economically with in-house architectural, construction, design, engineering, legal, management, leasing, marketing and financial departments. For more information, see http://www.hartzmountain.com/index.htm

About BioNeutral Group, Inc.

Headquartered at the New Jersey Institute of Technology/EDC in Newark, BioNeutral Group, Inc., is a technology-based life science company which has developed a technology platform that neutralizes harmful environmental contaminants, toxins and dangerous micro-organisms including bacteria, viruses, mold, fungi and spores. BioNeutral’s products, Ygiene and Ogiene, kill germs and clean surfaces with a dramatic increase in speed and power over their rivals in the marketplace. BioNeutral’s proprietary platform technology has been proven effective in surface, water and airborne applications. Its antimicrobial line of products under the Ygiene(TM) brand have been submitted to the EPA for approval for sale in the United States and has already been approved for sale in Germany and is permitted to be sold in the UK, France and Sweden. For more information, see www.bioneutralgroup.com

Forward-Looking Statements

This release contains certain “forward-looking statements” relating to the business of the Company and its subsidiary companies. These forward-looking statements are often identified by the use of forward-looking terminology such as “believes,” “expects” or similar expressions. Such forward looking statements involve known and unknown risks and uncertainties that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those described in the Company’s filings with the Securities and Exchange Commission. BioNeutral routinely tests its formulations against those of its competitors. The results are published to let shareholders know how the Company’s technology compares with known formulations in the market place. Any product claim for antimicrobial activity requires approval from the EPA or FDA, depending upon where and how the formulations are used. The EPA and FDA have not reviewed or confirmed the Company’s data and findings. BioNeutral’s antimicrobial formulations will be marketed under the brand name Ygiene(TM) and are not yet available for sale in the United States.


    PR/Media Relations:
    Stern & Co.
    Richard Stern, 212-888-0044
    richstern@sternco.com

    Investor Relations:
    Hayden IR
    Brett Maas, 646/536-7331
    brett@haydenir.com

    For The Company:
    BioNeutral Group, Inc.
    Stephen J. Browand, President and CEO
    973-286-2899
    steve@bioneutralgroup.com

SOURCE BioNeutral Group, Inc.


Source: newswire



comments powered by Disqus